<SEC-DOCUMENT>0001048477-25-000015.txt : 20250227
<SEC-HEADER>0001048477-25-000015.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227191535
ACCESSION NUMBER:		0001048477-25-000015
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250225
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Davis George Eric
		CENTRAL INDEX KEY:			0001380710
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26727
		FILM NUMBER:		25681772

	MAIL ADDRESS:	
		STREET 1:		C/O BIOMARIN PHARMACEUTICAL INC.
		STREET 2:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMARIN PHARMACEUTICAL INC
		CENTRAL INDEX KEY:			0001048477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680397820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
		BUSINESS PHONE:		4155066700

	MAIL ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wk-form4_1740701728.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-02-25</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001048477</issuerCik>
        <issuerName>BIOMARIN PHARMACEUTICAL INC</issuerName>
        <issuerTradingSymbol>BMRN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001380710</rptOwnerCik>
            <rptOwnerName>Davis George Eric</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BIOMARIN PHARMACEUTICAL INC.</rptOwnerStreet1>
            <rptOwnerStreet2>770 LINDARO STREET</rptOwnerStreet2>
            <rptOwnerCity>SAN RAFAEL</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94901</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>EVP, Chief Legal Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-02-25</value>
                <footnoteId id="F1"/>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>11040</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>67197</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-02-25</value>
                <footnoteId id="F1"/>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9660</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>76857</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-02-25</value>
                <footnoteId id="F1"/>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9367</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F5"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>86224</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.</footnote>
        <footnote id="F2">Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.</footnote>
        <footnote id="F3">Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.</footnote>
        <footnote id="F4">Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.</footnote>
        <footnote id="F5">Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Tae Sang Yoo, Attorney-in-Fact</signatureName>
        <signatureDate>2025-02-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
